QuidelOrtho Corporation (QDEL)

MedTech companies' quarterly results are likely to reflect base business recovery on a year-over-year basis. Let's see how HIMS, GMED, QDRL and HAE are poised ahead of their earnings release.

QuidelOrtho (QDEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

QuidelOrtho (QDEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company”) or (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care setti...

QuidelOrtho (QDEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

QDEL continues to witness growth on the back of its strong product portfolio.

QDEL introduces the Results Manager System, a powerful tool designed to streamline diagnostic data management, enhance efficiency, and improve patient care.

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”) announces the availability of the QuidelOrtho® Results Manager™ System, an informatics solution designed to address t...

Healthcare in vitro diagnostics company QuidelOrtho (QDEL 4.28%) attracted the right kind of attention from investors after posting its latest quarterly earnings report on Thursday. A rather encourage...

Despite solid performances by the Labs and Immunohematology units and China and Other regions, QDEL reports soft overall top-line results in fourth-quarter 2024.